45 States to Receive $105 Million from GlaxoSmithKline
GlaxoSmithKline, the British pharmaceutical company that manufactures the drugs Paxil and Wellbutrin, announced this week that the company has reached a $105 million settlement in a lawsuit brought by 45 U.S. states over alleged "off-label" and illegal marketing practices.
Under the terms of the settlement, GlaxoSmithKline admits no wrongdoing, but will pay $105 million to 45 states and the District of Columbia to settle the lawsuit, which alleges that the company illegally marketed the antidepressants Paxil and Wellbutrin for teenagers and children in violation of consumer protection laws. The two drugs are not approved by the FDA for use on minors.
The suit also claims that the company marketed Wellbutrin as an off-label treatment for weight loss and certain disorders such as attention deficit disorder, anxiety and bipolar disorder, all uses for which it was not approved by the FDA.
Of the 45 states involved in the lawsuit, California will receive the highest amount in settlement.